Reports
2023 TCFD Report
-
-
2023 TCFD Report
Samsung Biologics has issued 2023 TCFD Report aligned to the recommendations of the Task Force on Climate-Related Financial Disclosures (TCFD). As a leading sustainable CDMO partner, we understand the seriousness of climate change and its impact on public health; therefore, we are stepping up to the challenge of leading our industry towards a sustainable future. Through the TCFD report, we aim to transparently disclose climate-related financial risks, opportunities and business strategies, and provide more decision-useful information to various stakeholders.
- Reporting Period
-
This report covers the period from January 1, 2022 to December 31, 2022 in accordance with the CDP reporting standards and fiscal year criteria. Some matters of materiality herein cover the period up to the third quarter of 2023. For year-by-year comparison of quantitative data, data of four years from 2019 to 2022 are presented in parallel.
- Reporting Standards
-
This report is written in accordance with the TCFD recommendation.
- Reporting Scope
-
Emissions across the entire scope of Samsung Biologics’ business including upstream and downstream processes are estimated in accordance with the CDP standards. According to the 2022 consolidation criteria, Samsung Bioepis, a subsidiary, is included in Scope 1 & 2. Both financial and non-financial information, including entire climate-related performance, has all been prepared in accordance with fiscal years pursuant to our disclosure system. Data related to energy use and GHG emissions have been prepared in accordance with a third party verification.